BMYBristol Myers Squibb

$67.58

$41.6752 weeks$67.93

Price

$67.58+56%1Y

1M+9.8%1Y+56%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value57

Quality96

Momentum49

Growth38

Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.

In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR

P/E (TTM)14.9

Market Cap$110.27B

1Y Return+56%

5Y Return+21%

Business segments

Q1 2026 · $12.15B

The company’s own SEC segment disclosure.

Eliquis$4.14B34%
Opdivo$2.15B18%
Orencia$818.0M7%
Yervoy$651.0M5%
Other Growth Brands$581.0M5%
Reblozyl$555.0M5%
Other (16)$3.26B27%

Bristol Myers Squibb (BMY) reported revenue of $13.0B in Q2 2026 (quarter ended June 30, 2026), up 5.7% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $3.32B (26% of revenue). For the full year FY2025, revenue was $48.2B (−0.2% year on year) and net income $7.05B. Its largest product in 2026-Q1 was Eliquis at $4.14B, 34% of the disclosed total, just ahead of Opdivo at 18%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - General

Ranks #7 of 16 by Smart Score